Head-to-head · WeighScore
Ilant Health vs LVNG RX
The verdict
LVNG RX takes it — 62.5/100 to 56.8/100.
LVNG RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LVNG RX is a Delaware-registered telehealth platform (LVNG RX LLC) offering compounded semaglutide from $149/mo and tirzepatide from $249/mo, plus a lower-dose GLP-1 microdose program.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ilant Health | LVNG RX |
|---|---|---|
| WeighScore | 56.8/100 | 62.5/100 |
| Grade | C | C |
| Scorecard rank | #408 | #272 |
| Semaglutide | Not disclosed | $149/mo (starting dose, compounded) |
| Tirzepatide | Not disclosed | $249/mo (microdose tier, starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #408 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Graded #272 · C
Strengths
- One bundled price covers the provider visit, prescription, shipping and ongoing check-ins, with zero consultation charges
- States you are charged nothing if a provider does not approve you for treatment
- Promises no dose-change surcharges — 'the price we quote is the price you pay, period'
- Semaglutide from $149/mo is competitive against the wider compounded market
- Offers a lower-dose GLP-1 microdose program alongside standard semaglutide and tirzepatide
Where it loses points
- Displays a Trustpilot 'Rated Excellent 4.8 / 5' badge, but no Trustpilot profile exists for the domain or the brand
- Also claims '4.9 based on 300+ Google reviews'; no Google listing for the business could be located
- Its own homepage figures conflict — '10k+' members in the hero versus '1,743+ patients supported' in the counters below
- The actual plan price is confirmed only after provider review, and the three treatment pages publish no prices at all
- No compounding pharmacy, medical group or individual clinician is named anywhere on the site
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.